HC Wainwright Reiterates Buy Rating for PepGen (NASDAQ:PEPG)

PepGen (NASDAQ:PEPG)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $16.00 target price on the stock.

PEPG has been the topic of several other research reports. Bank of America lowered shares of PepGen from a “neutral” rating to an “underperform” rating and set a $3.00 price target on the stock. in a research note on Monday, December 16th. Wedbush lowered their price objective on shares of PepGen from $19.00 to $12.00 and set an “outperform” rating on the stock in a research note on Friday, November 8th.

PepGen Price Performance

Shares of PepGen stock opened at $1.71 on Monday. The business has a 50-day moving average of $2.46 and a 200-day moving average of $5.78. The company has a market capitalization of $55.75 million, a PE ratio of -0.57 and a beta of 1.53. PepGen has a 1-year low of $1.16 and a 1-year high of $19.30.

PepGen (NASDAQ:PEPG) last issued its earnings results on Monday, February 24th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.13. On average, equities analysts expect that PepGen will post -2.73 earnings per share for the current fiscal year.

Institutional Investors Weigh In On PepGen

A number of institutional investors have recently modified their holdings of PEPG. RTW Investments LP acquired a new stake in shares of PepGen in the 4th quarter valued at $12,102,000. Millennium Management LLC lifted its stake in shares of PepGen by 1,033.2% in the 4th quarter. Millennium Management LLC now owns 156,636 shares of the company’s stock valued at $594,000 after purchasing an additional 142,814 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in shares of PepGen in the 4th quarter valued at $516,000. Deutsche Bank AG lifted its stake in shares of PepGen by 442.5% in the 4th quarter. Deutsche Bank AG now owns 44,735 shares of the company’s stock valued at $170,000 after purchasing an additional 36,489 shares during the last quarter. Finally, Corton Capital Inc. acquired a new stake in shares of PepGen in the 4th quarter valued at $68,000. Institutional investors and hedge funds own 58.01% of the company’s stock.

PepGen Company Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.